Antitrust in the Pharmaceutical Sector: An Overview of U.S. Case Law
e-Competitions Bulletin, No. 88026, Nov. 2018
10 Pages Posted: 11 Nov 2018
Date Written: October 18, 2018
Abstract
In this overview, I summarize pharmaceutical antitrust law in the US and EU on settlements, product hopping, sample denials, citizen petitions, and rebates/bundling.
Keywords: Pharmaceutical, Antitrust, Settlements, Product Hopping, Sample Denials, Citizen Petitions, Rebates/Bundling
JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38
Suggested Citation: Suggested Citation
Carrier, Michael A., Antitrust in the Pharmaceutical Sector: An Overview of U.S. Case Law (October 18, 2018). e-Competitions Bulletin, No. 88026, Nov. 2018, Available at SSRN: https://ssrn.com/abstract=3269506
Do you have negative results from your research you’d like to share?
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.